We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

Producers to manage pharmaceuticals and sharps returned by consumers
  • Torys LLP
  • Canada
  • November 2 2012

On October 1, 2012, Collection of Pharmaceuticals and Sharps Responsibilities of Producers regulation (O. Reg. 29812) came into force


Canada’s PAAB releases updated Code of Advertising Acceptance
  • Torys LLP
  • Canada
  • December 7 2012

The Pharmaceutical Advertising Advisory Board (PAAB) has released a revised version of its Code of Advertising Acceptance


Health Canada to list authorized clinical trials online
  • Torys LLP
  • Canada
  • October 25 2012

On October 18, 2012, Health Canada issued a news release and subsequent Drugs and Health Products Notice announcing that it will create a web-based list of clinical trials authorized by Health Canada


Health Canada announces intent to develop a framework for orphan drug approval
  • Torys LLP
  • Canada, USA
  • October 5 2012

On October 3, 2012, Health Canada issued a press release announcing that it will develop a framework for the marketing approval of drugs to treat rare life-threatening, seriously debilitating or serious chronic rare diseases that are commonly referred to as "orphan drugs."


Canada's approach to functional foods
  • Torys LLP
  • Canada
  • April 21 2010

Today’s diet- and health-conscious environment has led to a proliferation of functional food marketing claims that advertise the specific health-enhancing characteristics of a food product


Ontario drug system reform now finalized
  • Torys LLP
  • Canada
  • June 17 2010

The Ontario government has published the final version of the amended regulations (final regulations) under the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA


Ontario drug system reform
  • Torys LLP
  • Canada
  • April 12 2010

The Ontario government has published proposed regulatory changes under the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act (DIDFA) that will affect the prices paid for generic drugs in both the public and private sector


Court affirms Health Canada’s broad discretion in review of drug submissions
  • Torys LLP
  • Canada
  • April 13 2010

In a recent decision of the Federal Court in Hospira Healthcare Corporation v. Canada (Attorney General) the Court affirmed that Health Canada has broad discretion in interpreting the Food and Drug Regulations to determine the content of an application for the marketing approval of a drug


Canadian and U.S. regulation of functional food claims
  • Torys LLP
  • Canada, USA
  • October 12 2010

In today's health-conscious marketplace, functional food labelling has grown into a multibillion dollar industry


Ontario companies doing business with hospitals may become subject to access-to-information requests
  • Torys LLP
  • Canada
  • April 6 2011

Pharmaceutical and medical device companies doing business with Ontario organizations that accept public funding, including hospitals, may be affected by recent legislative amendments aimed at increasing transparency and accountability of these entities